Navigation Links
MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbul, Turkey.

The oral and poster presentation entitled, "Efficacy and safety of a novel submicron particle formulation of budesonide for nebulized delivery in a 6 week study in 1-18 year old asthmatic children" will be presented on Monday, June 25th at 4:30pm local time.

In addition, the Company has a second poster presentation available for viewing at the conference. The second poster entitled, "Safety, tolerability, and pharmacokinetics of a novel submicron particle formulation of nebulized budesonide for the treatment of asthma" will be presented on Saturday, June 23rd at 4:30pm local time.

Unit Dose Budesonide is the Company's proprietary nebulized version of budesonide intended to treat pediatric asthma in children from six months to eight years of age. UDB is designed to be administered more quickly and to provide efficacy at lower doses than conventional nebulized budesonide, which is the current leading treatment for pediatric asthma. Potential faster delivery and efficacy at a lower dose together may offer improved safety, compliance and convenience for young patients who suffer from asthma.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprie tary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, ljohnson@mappharma.com

Web site: http://www.mappharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
(Date:5/23/2016)... 2016 According to a ... by Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, ... Care, Wound), Accessories (Lifting, Transfer) & by End ... by MarketsandMarkets, the patient handling equipment market is ... at a CAGR of 10.5% during the forecast ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
(Date:5/26/2016)... Warner, New Hampshire (PRWEB) , ... May 26, 2016 , ... ... of which are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech ... known to provide reliable monitoring solutions trusted by government agencies, including NASA. , ...
(Date:5/26/2016)... SURPRISE, ARIZ. (PRWEB) , ... May 26, 2016 , ... ... worry of American families. , The 550 employees of Sun Health Senior Living ... plan through Aetna that reduces their doctor and prescription copays for the year, while ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center hosted ... Club in Cypress. With the help of community partners, the event organizers raised $45,000 ... hope for wounded service members and their families through health, wellness, and therapeutic support. ...
Breaking Medicine News(10 mins):